Decapinol Gel, offers a novel and convenient way of treating periodontal disease. It contains 3 key ingredients - Delmopinol Hydrochloride (5mg/ml), Polyvinylpyrrolidone (PVP) and Hyaluronic Acid.

Its key ingredient is the cationic surfactant Delmopinol hydrochloride (5mg/ml) and its unique mode of action prevents the attachment as well as the adherence of plaque bacteria to the teeth.

Delmopinol Hydrochloride helps to treat and prevent gingivitis and periodontitis, and reduce periodontal pocket depth through its application along the gingival margin and into interdental spaces.

Its key ingredient is the cationic surfactant Delmopinol hydrochloride (5mg/ml) and its unique mode of action prevents the attachment as well as the adherence of plaque bacteria to the teeth, gingiva and to itself . This interference with the plaque build-up process prevents the onset of gingivitis that can lead to periodontitis.

It also interferes with the enzyme GTF, which is responsible for the production of glucans (the glue or cement that is critical for plaque build-up). This results is less cohesive and less adhesive plaque bacteria, making it easier to remove by conventional tooth brushing techniques.   

It also maintains a healthy composition of oral bacteria.

PVP & Hyaluronic Acid (barrier forming agents) help to provide pain relief of minor oral lesions/irritations and localised trauma following scaling and root planing (SRP), tooth extraction, implant surgery and periodontal surgery. Through this "liquid bandage" mechanism of action, gingival bleeding is reduced, local pain relief given and both ingredients facilitate the natural healing process of the soft gingival tissue following treatment.

Decapinol Gel offers patients versatility and convenience in treating specific areas within the mouth. It is available in a 16ml tube and a 4ml sample tube, and can be used by both clinicians and patients alike.

Disease overview

Gingivitis is a non-specific term used to describe an inflammation of the gums (gingiva), regardless of the ætiology, and affects approximately 80-90% of the adult population . Plaque-associated gingivitis is an inflammation of the interdental and gingival margin that can be controlled or prevented by removing and/or inhibiting microbial plaque accumulation.

Periodontitis is a more serious condition, involving inflammation of the periodontium, the areas surrounding the teeth - this usually affects 13%-15% of the adult population . The structures that anchor the teeth to the bone are affected - there may be apical migration of epithelial attachment and loss of alveolar bone leading to tooth and bone loss.

Gingivitis always precedes periodontitis and so prevention or treatment of gingivitis is considered an accepted method of preventing periodontitis

Stage of development

In the European Union, Decapinol Gel is registered as a Class IIb medical device, and has as such been awarded a CE mark. The Medical Device Directive applies to all European Union countries, which means Decapinol Gel can be sold freely within these countries, without further registration requirements. The CE mark signifies the product's conformity with the Directive.

In the United States, Decapinol Gel has been approved by the FDA, and classified as a Class II Medical Device, as a prescription only product.

 

Registered

Patents pending - Please refer to Sinclair's Business Development team for an update on Decapinol IP situation.

 

 

Marketing companies are required to sell Decapinol in key territories around the world.